Dr. Sundram has strong experience in protein expression technologies, molecular biology, biochemistry, peptidomimetics and in drug delivery systems. Prior to starting Recombinant Technologies in 1998, he was trained at Yale School of Medicine for a decade. At Yale, Dr. Sundaram contributed in the research and development of a vaccine to treat human papilloma virus in a rabbit model. This work formed the basis for Merck in developing the vaccine for HPV 16, which is currently marketed as 'Gardasil'. Dr. Sundaram's research is acknowledged on the Merck's patent for the above vaccine.
Dr. Sundaram's research followed by a clinical trial on a herbal medicine for his doctoral thesis research translated to a marketable drug in India to treat coronary heart disease.